These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 20370845)

  • 1. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain.
    Sandner-Kiesling A; Leyendecker P; Hopp M; Tarau L; Lejcko J; Meissner W; Sevcik P; Hakl M; Hrib R; Uhl R; Dürr H; Reimer K
    Int J Clin Pract; 2010 May; 64(6):763-74. PubMed ID: 20370845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain.
    Simpson K; Leyendecker P; Hopp M; Müller-Lissner S; Löwenstein O; De Andrés J; Troy Ferrarons J; Bosse B; Krain B; Nichols T; Kremers W; Reimer K
    Curr Med Res Opin; 2008 Dec; 24(12):3503-12. PubMed ID: 19032132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial.
    Leng X; Zhang F; Yao S; Weng X; Lu K; Chen G; Huang M; Huang Y; Zeng X; Hopp M; Lu G
    Adv Ther; 2020 Mar; 37(3):1188-1202. PubMed ID: 32020565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain.
    Vondrackova D; Leyendecker P; Meissner W; Hopp M; Szombati I; Hermanns K; Ruckes C; Weber S; Grothe B; Fleischer W; Reimer K
    J Pain; 2008 Dec; 9(12):1144-54. PubMed ID: 18708300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a fixed-dose opioid agonist/antagonist on constipation in patients on long-term opioids for non-malignant pain unable to tolerate laxatives.
    Mehta V; Alaward S; Kuravinakop S; Nikolic S
    Pain Physician; 2014; 17(5):415-24. PubMed ID: 25247899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial.
    Löwenstein O; Leyendecker P; Hopp M; Schutter U; Rogers PD; Uhl R; Bond S; Kremers W; Nichols T; Krain B; Reimer K
    Expert Opin Pharmacother; 2009 Mar; 10(4):531-43. PubMed ID: 19243306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study.
    Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
    Eur J Pain; 2017 Oct; 21(9):1485-1494. PubMed ID: 28474460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis.
    Lazzari M; Greco MT; Marcassa C; Finocchi S; Caldarulo C; Corli O
    Drug Des Devel Ther; 2015; 9():5863-72. PubMed ID: 26586937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trials.
    Blagden M; Hafer J; Duerr H; Hopp M; Bosse B
    Neurogastroenterol Motil; 2014 Dec; 26(12):1792-801. PubMed ID: 25346155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixed ratio (2:1) prolonged-release oxycodone/naloxone combination improves bowel function in patients with moderate-to-severe pain and opioid-induced constipation refractory to at least two classes of laxatives.
    Koopmans G; Simpson K; De Andrés J; Lux EA; Wagemans M; Van Megen Y
    Curr Med Res Opin; 2014 Nov; 30(11):2389-96. PubMed ID: 25265132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials.
    Löwenstein O; Leyendecker P; Lux EA; Blagden M; Simpson KH; Hopp M; Bosse B; Reimer K
    BMC Clin Pharmacol; 2010 Sep; 10():12. PubMed ID: 20920236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial.
    Baron R; Jansen JP; Binder A; Pombo-Suarez M; Kennes L; Müller M; Falke D; Steigerwald I
    Pain Pract; 2016 Jun; 16(5):600-19. PubMed ID: 26554630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid-Induced Constipation Relief From Fixed-Ratio Combination Prolonged-Release Oxycodone/Naloxone Compared With Oxycodone and Morphine for Chronic Nonmalignant Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Huang L; Zhou JG; Zhang Y; Wang F; Wang Y; Liu DH; Li XJ; Lv SP; Jin SH; Bai YJ; Ma H
    J Pain Symptom Manage; 2017 Nov; 54(5):737-748.e3. PubMed ID: 28736104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR.
    Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
    Eur J Pain; 2017 Oct; 21(9):1528-1537. PubMed ID: 28641363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain.
    Ahmedzai SH; Nauck F; Bar-Sela G; Bosse B; Leyendecker P; Hopp M
    Palliat Med; 2012 Jan; 26(1):50-60. PubMed ID: 21937568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged-Release Oxycodone/Naloxone Improves Anal Sphincter Relaxation Compared to Oxycodone Plus Macrogol 3350.
    Poulsen JL; Brock C; Grønlund D; Liao D; Gregersen H; Krogh K; Drewes AM
    Dig Dis Sci; 2017 Nov; 62(11):3156-3166. PubMed ID: 28986667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study.
    Hermanns K; Junker U; Nolte T
    Expert Opin Pharmacother; 2012 Feb; 13(3):299-311. PubMed ID: 22224497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxycodone/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation.
    Burness CB; Keating GM
    Drugs; 2014 Mar; 74(3):353-75. PubMed ID: 24452879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone.
    Morlion B; Clemens KE; Dunlop W
    Clin Drug Investig; 2015 Jan; 35(1):1-11. PubMed ID: 25479959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain.
    Ahmedzai SH; Leppert W; Janecki M; Pakosz A; Lomax M; Duerr H; Hopp M
    Support Care Cancer; 2015 Mar; 23(3):823-30. PubMed ID: 25218610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.